F. Rivera Herrero
About
F. Rivera Herrero is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, F. Rivera Herrero has authored 19 papers receiving a total of 75 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Surgery. Recurrent topics in F. Rivera Herrero's work include Colorectal Cancer Treatments and Studies (9 papers), Gastric Cancer Management and Outcomes (5 papers) and Lung Cancer Treatments and Mutations (5 papers). F. Rivera Herrero is often cited by papers focused on Colorectal Cancer Treatments and Studies (9 papers), Gastric Cancer Management and Outcomes (5 papers) and Lung Cancer Treatments and Mutations (5 papers). F. Rivera Herrero collaborates with scholars based in Spain, United States and United Kingdom. F. Rivera Herrero's co-authors include Javier Espinosa, Aranzazu González del Alba, Esther Holgado, Javier Sastre Valera, Dolores Isla, María Lomas Garrido, Encarnación González‐Flores, Josep Tabernero, Marc Peeters and Jóse Ángel Arranz Arija and has published in prestigious journals such as Annals of Oncology, European Journal of Cancer and Clinical & Translational Oncology.
In The Last Decade
F. Rivera Herrero
16 papers receiving 74 citations
Peers
F. Rivera Herrero
Shuaixi Yang China
Fabio Gelsomino Italy
Hanneke van der Wijngaart Netherlands
Béla Pikó Hungary
Sabela Recalde Spain
Serena Macrini Italy
Cheng Tzu Yen Brazil
Brittanie M Millang United States
Dafina Nikolova North Macedonia
Reetta Peltonen Finland
Citations per year, relative to F. Rivera Herrero F. Rivera Herrero (= 1×)
peers
Shuaixi Yang
Countries citing papers authored by F. Rivera Herrero
Since
Specialization
Citations
This map shows the geographic impact of F. Rivera Herrero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Rivera Herrero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Rivera Herrero more than expected).
Fields of papers citing papers by F. Rivera Herrero
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by F. Rivera Herrero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Rivera Herrero. The network helps show where F. Rivera Herrero may publish in the future.
Co-authorship network of co-authors of F. Rivera Herrero
This figure shows the co-authorship network connecting the top 25 collaborators of F. Rivera Herrero. A scholar is included among the top collaborators of F. Rivera Herrero based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Rivera Herrero. F. Rivera Herrero is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Montagut, Clara, Joana Vidal, Vicente Alonso-Orduña, et al.. (2025). LBA33 Circulating tumor (ct) DNA-guided anti-EGFR rechallenge strategy in metastatic colorectal cancer (mCRC): Final results of the phase II randomized CITRIC trial. Annals of Oncology. 36. S1576–S1577.
2.
Al-Batran, S-E., Woo Jin Hyung, M. Moehler, et al.. (2025). LBA4 Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. Annals of Oncology. 36. S150–S151.
3.
Yoshino, Takayuki, Diana Younan, Kei Muro, et al.. (2024). A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness. European Journal of Cancer. 202. 113975–113975.
4.
Alonso-Orduña, Vicente, F. Rivera Herrero, L. Layos Romero, et al.. (2024). 511MO Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: The randomized phase II CITRIC trial. Annals of Oncology. 35. S433–S434.
5.
Lewis, Katie, et al.. (2024). 463P A real-world study to evaluate biomarker testing and treatment management in patients with locally advanced unresectable or metastatic G/GEJ adenocarcinoma in France, Germany, Italy, Spain, UK and Canada: Adelphi Real World G/GEJ cancer disease specific programme. Annals of Oncology. 35. S185–S185.
6.
Herrero, F. Rivera, D-Y. Oh, Jin‐Shing Chen, et al.. (2024). 1422P First-line rilvegostomig (rilve) + chemotherapy (CTx) in patients (pts) with HER2-negative (HER2–) locally advanced unresectable or metastatic gastric cancers: First report of GEMINI-Gastric sub study 2. Annals of Oncology. 35. S887–S887.
7.
Mercadé, T. Macarulla, et al.. (2024). 331P Phase Ib/IIa study to evaluate safety and efficacy of priming treatment with the hedgehog inhibitor NLM-001 prior to gemcitabine and nab-paclitaxel plus zalifrelimab as first-line treatment in patients with advanced pancreatic cancer: NUMANTIA study. Annals of Oncology. 35. S139–S140.
8.
Yamamoto, Shun, Chin‐Yo Lin, F. Rivera Herrero, et al.. (2023). 189P Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC). Annals of Oncology. 34. S1548–S1548.
9.
André, Thierry, Kai‐Keen Shiu, Benny Vittrup Jensen, et al.. (2021). O-8 Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer. Annals of Oncology. 32. S220–S221.
10.
Ko, Andrew H., Antonio Cubillo, Madappa N. Kundranda, et al.. (2018). CARRIE: A randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer. Annals of Oncology. 29. viii720–viii720.
11.
González‐Flores, Encarnación, Vicente Alonso, Patricia Gómez, et al.. (2018). In the pathway to response: Is aflibercept an optimal treatment for RASwt mCRC patients after progression to 1st line containing anti-EGFR?. Annals of Oncology. 29. viii160–viii161.
12.
Herrero, F. Rivera, Dominik Paul Modest, Filippo de Braud, et al.. (2017). Outcomes in patients receiving maintenance therapy in two panitumumab (Pmab) first-line trials for metastatic colorectal cancer (mCRC). Annals of Oncology. 28. v176–v176.
13.
Philip, P. A., Jill Lacy, Alberto F. Sobrero, et al.. (2017). nab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): Interim efficacy and safety results from the Phase 2 LAPACT Trial. Annals of Oncology. 28. v212–v212.
14.
Taı̈eb, Julien, Marc Peeters, Salvatore Siena, et al.. (2016). Importance of tumour symptoms and extent of disease on efficacy of first-line FOLFOX4 ± panitumumab (pmab) in patients (pts) with RAS wild-type (WT)/BRAF WT metastatic colorectal cancer (mCRC) in the PRIME study. Annals of Oncology. 27. vi159–vi159.
15.
Siena, Salvatore, F. Rivera Herrero, Jean‐Yves Douillard, et al.. (2016). Impact of depth of response (DpR) on survival in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line panitumumab + FOLFOX4 vs FOLFOX4. Annals of Oncology. 27. vi160–vi160.
16.
Arija, Jóse Ángel Arranz, Javier Espinosa, Miguel Á. Climent Durán, & F. Rivera Herrero. (2012). SEOM clinical guidelines for treatment of prostate cancer. Clinical & Translational Oncology. 14(7). 520–527.
17.
Espinosa, Javier, Aranzazu González del Alba, F. Rivera Herrero, & Esther Holgado. (2012). SEOM guidelines for the treatment of bone metastases from solid tumours. Clinical & Translational Oncology. 14(7). 505–511.
18.
Herrero, F. Rivera, Javier Sastre Valera, Josep Tabernero, et al.. (2010). SEOM clinical guidelines for the adjuvant treatment of colorectal cancer. Clinical & Translational Oncology. 12(11). 724–728.
19.
Díaz‐Rubio, Eduardo, A. Antón Torres, Enrique Aranda, et al.. (2005). A panel discussion of controversies and challenges in the adjuvant treatment of colon cancer. Clinical & Translational Oncology. 7(1). 3–11.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Shuaixi Yang Breakdown of academic impact, for papers by Fabio Gelsomino Breakdown of academic impact, for papers by Hanneke van der Wijngaart Breakdown of academic impact, for papers by Béla Pikó Breakdown of academic impact, for papers by Sabela Recalde Breakdown of academic impact, for papers by Serena Macrini Breakdown of academic impact, for papers by Cheng Tzu Yen Breakdown of academic impact, for papers by Brittanie M Millang Breakdown of academic impact, for papers by Dafina Nikolova Breakdown of academic impact, for papers by Reetta Peltonen